Dynavax Technologies Corporation (DVAX) Stock Analysis

Dynavax Technologies Corporation (DVAX) is a publicly traded company in the HEALTHCARE sector. It trades at $15.50. This page summarizes the public market data, fundamentals, and frequently asked questions for DVAX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $15.50

Market Sentiment

Dynavax Technologies Corporation currently has a Bearish sentiment score of -0.16.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation (DVAX) is a biopharmaceutical firm based in Emeryville, California, focused on the development and commercialization of innovative vaccines aimed at addressing major public health challenges. The company is recognized for its proprietary immunotherapy platform which enhances vaccine efficacy, exemplified by its lead product, HEPLISAV-B, a hepatitis B vaccine approved in the U.S. and various international markets. With a promising pipeline and strong strategic ...

GNG Research Analysis

GNG Research scores Dynavax Technologies Corporation (DVAX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for DVAX.

Frequently Asked Questions

Does DVAX pay dividends?

Dynavax Technologies Corporation (DVAX) does not currently pay a regular dividend.